9 Meters Biopharma Q2 FY22: net loss $11.1M; diluted EPS −$0.80

Key figures from this report

These are the numbers 9 Meters Biopharma reported for Q2 FY22, the quarter ended Jun 30, 2022, as tagged in the filing’s XBRL data, each against the same quarter a year earlier. A plain-English reading of this report is not written yet.

1. Net income−$11.1MAgainst −$8.3M in Q2 FY2110-Q income statement, on EDGAR
2. Diluted EPS−$0.80Against −$0.60 in Q2 FY21. Split-adjusted, as the tables show it; the filing reported −$0.0410-Q income statement, on EDGAR
3. Cash and cash equivalents$29.5M−54% from $64.0M in Q2 FY2110-Q balance sheet, on EDGAR
4. Cash from operations−$7.8MAgainst −$7.1M in Q2 FY2110-Q cash flow statement, on EDGAR; the filing reports year-to-date cash flows; this quarter is the year-to-date total less the earlier quarters